Icon (ICLR) Expected to Announce Quarterly Earnings on Wednesday

Icon (NASDAQ:ICLR) is anticipated to issue its Q3 2025 results after the market closes on Wednesday, October 22nd. Analysts expect the company to announce earnings of $3.28 per share and revenue of $1.9848 billion for the quarter. Icon has set its FY 2025 guidance at 13.000-14.000 EPS.Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, October 23, 2025 at 8:00 AM ET.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $3.26 EPS for the quarter, topping analysts’ consensus estimates of $3.18 by $0.08. Icon had a return on equity of 10.95% and a net margin of 9.82%.The firm had revenue of $2.02 billion during the quarter, compared to analyst estimates of $1.98 billion. During the same period last year, the company posted $3.75 EPS. The business’s quarterly revenue was down 4.8% compared to the same quarter last year. On average, analysts expect Icon to post $13 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Icon Trading Up 1.8%

Shares of NASDAQ ICLR opened at $188.45 on Tuesday. Icon has a one year low of $125.10 and a one year high of $300.25. The firm has a market capitalization of $15.22 billion, a PE ratio of 19.39, a PEG ratio of 2.75 and a beta of 1.23. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.35. The business has a 50-day moving average price of $177.75 and a two-hundred day moving average price of $157.51.

Analyst Ratings Changes

ICLR has been the subject of a number of research reports. Barclays raised their price objective on Icon from $180.00 to $190.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 2nd. Jefferies Financial Group lowered Icon from a “buy” rating to a “hold” rating and reduced their price target for the company from $220.00 to $175.00 in a report on Tuesday, September 9th. UBS Group lifted their price target on Icon from $170.00 to $240.00 and gave the company a “buy” rating in a report on Friday, July 25th. Robert W. Baird lifted their price target on Icon from $222.00 to $224.00 and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Icon in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, Icon has an average rating of “Moderate Buy” and an average target price of $210.64.

Institutional Investors Weigh In On Icon

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geneos Wealth Management Inc. lifted its holdings in Icon by 11.5% in the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after purchasing an additional 56 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Icon by 58.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock worth $113,000 after buying an additional 289 shares during the period. Peapack Gladstone Financial Corp bought a new position in Icon in the 2nd quarter worth approximately $212,000. WINTON GROUP Ltd bought a new position in Icon in the 2nd quarter worth approximately $254,000. Finally, White Knight Strategic Wealth Advisors LLC bought a new position in Icon in the 2nd quarter worth approximately $262,000. 95.61% of the stock is currently owned by institutional investors and hedge funds.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.